1. A multiobserver study investigating the effectiveness of prostatic multiparametric magnetic resonance imaging to dose escalate corresponding histologic lesions using high-dose-rate brachytherapy
- Author
-
Christopher W. Smith, Glenn Bauman, Derek W. Cool, Aaron D. Ward, Matthew Bastian-Jordan, Douglas A. Hoover, David D'Souza, Stephen E. Pautler, Jose A. Gomez, Zahra Kassam, Joseph L. Chin, Madeleine Moussa, and Kathleen Surry
- Subjects
Male ,medicine.medical_treatment ,Brachytherapy ,Pilot Projects ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Multiparametric Magnetic Resonance Imaging ,Radiation treatment planning ,Retrospective Studies ,Dose escalation ,business.industry ,Prostatectomy ,Standard treatment ,Prostatic Neoplasms ,Cancer ,Radiotherapy Dosage ,medicine.disease ,Magnetic Resonance Imaging ,High-Dose Rate Brachytherapy ,3. Good health ,Oncology ,High-dose-rate brachytherapy ,030220 oncology & carcinogenesis ,mpMRI ,Nuclear medicine ,business - Abstract
Purpose Using multiparametric MRI data and the pathologic data from radical prostatectomy specimens, we simulated the treatment planning of dose-escalated high-dose-rate brachytherapy (HDR-BT) to the Multiparametric MRI dominant intraprostatic lesion (mpMRI-DIL) to compare the dose potentially delivered to the pathologically confirmed locations of the high-grade component of the cancer. Methods and Materials Pathologist-annotated prostatectomy midgland histology sections from 12 patients were registered to preprostatectomy mpMRI scans that were interpreted by four radiologists. To simulate realistic HDR-BT, we registered each observer's mpMRI-DILs and corresponding histology to two transrectal ultrasound images of other HDR-BT patients with a 15-Gy whole-gland prescription. We used clinical inverse planning to escalate the mpMRI-DILs to 20.25 Gy. We compared the dose that the histopathology would have received if treated with standard treatment plans to the dose mpMRI-targeting would have achieved. The histopathology was grouped as high-grade cancer (any Gleason Grade 4 or 5) and low-grade cancer (only Gleason Grade 3). Results 212 mpMRI-targeted HDR-BT plans were analyzed. For high-grade histology, the mpMRI-targeted plans achieved significantly higher median [IQR] D98 and D90 values of 18.2 [16.7–19.5] Gy and 19.4 [17.8–20.9] Gy, respectively, in comparison with the standard plans (p = 0.01 and p = 0.003). For low-grade histology, the targeted treatment plans would have resulted in a significantly higher median D90 of 17.0 [16.1–18.4] Gy in comparison with standard plans (p = 0.015); the median D98 was not significantly higher (p = 0.2). Conclusions In this retrospective pilot study of 12 patients, mpMRI-based dose escalation led to increased dose to high-grade, but not low-grade, cancer. In our data set, different observers and mpMRI sequences had no substantial effect on dose to histologic cancer.
- Published
- 2021
- Full Text
- View/download PDF